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Abstract 
Background: Drugs’ pharmacokinetics and pharmacodynamics can be af-
fected by diverse genetic variations, within which simple nucleotide poly-
morphisms (SNPs) are the most common. Genetic variability is one of the 
factors that could explain questions like why a given drug does not have the 
desired effect or why do adverse drug reactions arise. 
Methods: In this retrospective observational study, literature search limits 
were set within PubMed database as well as the epidemiological bulletins 
published by the Mexican Ministry of Health, from Jan 1st 2001 to Mar 31st 
2017 (16 years).  
Results: Metabolism of antiparasitic drugs and their interindividual re-
sponses are mainly modified by variations in cytochrome P450 enzymes. 
These enzymes show high frequencies of polymorphic variability thus af-
fecting the expression of CYP2C, CYP2A, CYP2A6, CYP2D6, CYP2E6 
and CYP2A6 isoforms. Research in this field opens the door to new person-
alized treatment approaches in medicine. 
Conclusion: Clinical and pharmacological utility yield by applying phar-
macogenetics to antiparasitic treatments is not intended as a mean to im-
prove the prescription process, but to select or exclude patients that could 
present adverse drug reactions as well as to evaluate genetic alterations 
which result in a diversity of responses, ultimately seeking to provide a more 
effective and safe treatment; therefore choosing a proper dose for the ap-
propriate patient and the optimal treatment duration. Furthermore, phar-
macogenetics assists in the development of vaccines. In other words, the 
aim of this discipline is to find therapeutic targets allowing personalized 
treatments. 
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Introduction 
 
arasitic infections have historically had 
repercussions in the areas of health, 
society, and politics. These diseases are 
comprised of infections produced by protozo-
ans, helminthes or ectoparasites. Their im-
portance, based on the frequency, is 
geohelminthiasis, protozoan intestinal infec-
tion, malaria, schistosomiasis and lymphatic 
filariasis (1). 
Probably, the parasitic infection having the 
most impact on human health, on a global 
scale, is malaria, for which an approximate 
annual mortality of 584000 people is reported, 
followed by protozoan intestinal infection, 
leishmaniasis and African trypanosomiasis (2-
4). 
 
Methods 
  
   In this retrospective observational study, 
literature search limits were set within Pub-
Med database as well as the epidemiological 
bulletins published by the Mexican Ministry of 
Health, from January 1st 2001 to March 31st 
2017 (16 years).  
 
Results and Discussion 
 
Parasitic Intestinal Infections  
Diseases related to intestinal parasites con-
tinue to be the most common cause of chron-
ic endemic infections in developing countries 
found in tropical and subtropical areas, reason 
for which WHO has designated them as 
NTDs (Neglected Tropical Diseases) or non-
attended tropical diseases. This classification is 
based on the following characteristics: geo-
graphical localization (tropical or subtropical, 
priority within health strategy plans, insuffi-
cient research, limited research funding and 
little intervention (5). 
Due to a variety of eco-social factors such as 
ecological and climatic change, anthropogenic 
effects, such as human migration, urbanization, 
and industrialization, besides variation in host 
susceptibility towards parasites, together with 
genetic changes observed in parasites, as well 
as in their hosts. Infections caused by parasites 
present changes in their incidence and patho-
genicity (6-8), insomuch that the prevalence of 
these diseases in the present day is not only 
rising in developing countries but also devel-
oped countries. To illustrate the aforemen-
tioned, in one of the reports generated by the 
Panamerican Health Organization (OPS) (9) , 
in 14 countries in Latin America the preva-
lence of geohelminths is greater than 20% and 
in some cases it can reach 90%. These infec-
tions are considered by the WHO as a “gener-
alized public health issue”. 
One example that shows the rise in preva-
lence of parasitic infections in developed 
countries is that of two cohort studies done in 
France, where an increase in the presence of 
an intestinal protozoan, from 3% to 6.1% was 
observed (10); although not enough to reach 
the minimum threshold established by the 
WHO to be considered a public health issue 
(20%), this increase does reflect the need to 
review hygiene measures for water and food 
handling, as well as the migration of people 
from developing countries (11). 
Despite the efforts to reduce the prevalence 
of parasitosis, there has been no significant 
change. There are more than 2 billion persons 
infected with at least one species of intestinal 
parasite and 4 billion having a risk of infection 
(12). 
Human beings can be hosts to more than 72 
genuses of protozoans and helminths, includ-
ing the following: Plasmodium, Trypanosoma, 
Leishmania, Giardia, Entamoeba, Blastocystis, En-
terobius, Cistoisospora, Cyclospora, Cryptosporidium, 
Balantidium, Toxoplasma, Enterocytozoon, Encepha-
litozoon, Ascaris, Trichuris, Necator, Ancylostoma, 
Onchocerca, Hymenolepis, Taenia, to name a few. 
P 
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Several of these geniuses can cause intestinal 
parasitic infections, which continue to be a 
serious health issue, especially in countries 
with greater poverty; being the lead cause of 
parasitosis the contamination of food and wa-
ter with fecal matter (13, 14). 
 
Intestinal parasites of medical importance 
and their classification  
In this review, the traditional classification 
for parasites in humans is considered, adapted 
for its application to medical practice (15) 
(Table 1). 
 
Impact of parasitosis on the health of the 
Mexican population  
Mexico has a population of 119530753 in-
habitants, according to the 2015 National 
census survey. Public health system reports 
epidemiological data indicating that more than 
69% of people present intestinal parasitosis by 
pathogenic or commensal agents. 
Among the causal agents most frequently as-
sociated, are the following: Entamoeba histolytica, 
Giardia lamblia, and Blastocystis spp. (protozo-
ans); Ascaris lumbricoides, Trichuris trichiura, Hy-
menolepis nana, Taenia saginata y Taenia solium 
(helminths). Population studies report a fre-
quency of 12% for parasitosis, identifying the 
presence of two or more intestinal parasites 
(16-18).  
In Mexico, the national system of epidemio-
logical surveillance (SINAVE) informs, 
through periodic bulletins, data on morbidity 
of diseases subject to epidemiological surveil-
lance, in which intestinal parasitosis are found 
and considered a public health issue due to the 
magnitude of their incidence. 
Likewise its transcendence is linked overall 
to secondary diseases such as anemia and sur-
gical complications that occur in the cases of 
uncinariasis and ascariasis (18). 
  
Table 1: Classification of the parasites which infect humans having major medical interest, adapted for its 
application to medical practice (15) 
 
 Protozoans Amoebas 
 Flagellated 
Sporozoos or Apicomplexa (coccidia) 
Ciliates 
Microsporidia (still considered to be fungi, for their genomics and proteomics) 
“Others”, in which Blastocystis is found 
Helminths Nematodes 
Flatworms Tapeworms 
Trematodes 
 
The broad geographical and socio-
demographic diversity of Mexico allows for a 
high incidence in intestinal parasitosis among 
the general population According to the mor-
bidity yearbook of 2015, an incidence rate of 
279.28 per 100000 inhabitants corresponds to 
protozoan and 206.73 per 100000 inhabitants 
to helminth infections. This data evidences the 
importance of diagnosis, treatment, and pre-
vention of intestinal parasitosis (19). Parasito-
sis affect physical growth and cognitive devel-
opment in boys and girls (20). 
 
Antiparasitics used in Mexico  
Antiparasitic treatment has evolved over the 
last century, from the use of antimonial inor-
ganic compounds with activity against tissue 
protozoans such as Leishmania, to arsenic 
based preparations (i.e. Fowler’s arsenical liq-
uor, an aqueous-alcoholic solution of sodium 
arsenite) as well as azoic colorants such as try-
pan blue; the two latter showing trypanocidal 
activity. Nitroimidazole ring molecules such as 
metronidazole (the drug of choice against pro-
tozoans) and heterocyclic nitrogenated com-
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pounds such as nitazoxanide have a broad an-
tiparasitic spectrum (4, 17, 21, 22). 
Currently, control of parasitic infections is 
mainly based on the use of drugs, because 
there are only a limited number of vaccines 
available against a few parasites (23). 
The antiparasitic treatment applied in Mexi-
co comprises drugs targeted against intestinal 
parasites, most commonly metronidazole, al-
bendazole, mebendazole, nitazoxanide, 
tinidazole and secnidazole, for which an effi-
cacy between 80% and 95% is reported. These 
drugs present adverse reactions such as ab-
dominal pain, nausea, vomit and alterations of 
taste in cases where treatment duration is 
greater than 48 hours (4,16-18). 
Furthermore, for conventional regimes con-
sisting of metronidazole, tinidazole and al-
bendazole, treatment failures have been re-
ported in approximately 20% of cases (24). 
The action of antiparasitics is based on its ca-
pacity of binding to certain sites of the parasit-
ic structure and to inhibit important cellular 
functions (14). The majority of antiparasitic 
drugs usually have one of the following mech-
anisms of action (4):  
a) Affectation of biosynthetic 
metabolism: antiprotozoan drugs. 
b) Alteration of energetic me-
tabolism, structural proteins or 
neuromuscular function: antihel-
minthic drugs. 
The pharmacological targets of antiparasitics 
are mainly: receptors (nuclear, membrane or 
cytoplasmic), transport molecules, enzymes 
and ionic channels (25) (Fig. 1).  
A brief of the inhibition mechanisms for 
proteins and structural molecules, as well as 
the biochemical mechanisms for selective ac-
tion of the most representative antiparasitic 
drugs can be observed in Tables 2 and 3. 
Next, we display some antiparasitics and 
their pharmacological targets, which are indi-
cated by Arabic numbers: 1. Proguanil, 2. 
Benznidazole, Nifurtimox, Chloroquine, Qui-
nine, Metronidazole, 3. Amphotericin B, 4. 
Primaquine, 5. Chloroquine, 6. Albendazole, 
Mebendazole, triclabendazole, Praziquantel, 
Ivermectin (Fig. 1). 
 
 
 
Fig. 1: Pharmacological targets of main antiparasitic drugs of medical importance in humans (4) 
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Table 2: Mechanism of inhibition of proteins and structural molecules (4, 21, 25) 
 
Inhibitors Drug Mechanism Parasite Example 
Of cofactor synthesis 
 
Sulphonamides 
(sulphadoxine) 
Blockage of tetrahydrofolate biosynthe-
sis, necessary in the synthesis of DNA  
(sulphadoxine, antagonist of 
paraaminobenzoic acid, is used to fix the 
dihydropteroate synthetase; it is adminis-
tered with pyrimethamine; trimethoprim 
and proguanil inhibit dihydrofolate re-
ductase  
Sporozoos 
(coccidia) 
Plasmodium spp. 
Sulfones 
(dapsone) 
Diaminopyrimidines 
(trimethoprim, 
pyrimethamine) 
Proguanil 
Of the synthesis of 
nucleic acids 
Chloroquines, 
Quinine 
 
They insert themselves into the sequence 
of base pairs  
(Chloroquine inhibits polymerase) 
Protozoans: 
(sporozoos-
coccidia), 
anaerobic 
 
Trypanosoma cruzi 
Blastocystis spp. 
Giardia lamblia 
Diamidines (pen-
tamidine) 
 
They intercalate between base pairs and 
act ionically  
Benznidazole 
Nifurtimox 
Metronidazole 
Tinidazole 
Nitrogen group activation alkylates DNA  
Of membrane synthesis Amphotericin B Fixes itself to ergosterol, altering the 
permeability of the membrane, allowing 
the exit of K+ and other moleculas, in 
addition to oxidative process. 
Protozoans: 
Tissue y 
free-living 
amoebas  
Leishmania spp. 
Naegleria spp. 
Of enzymes related to 
energetic metabolism  
Melarsoprol  
(arsenicales trivalentes) 
Estibogluconato 
sódico  
Antimoniato de 
meglumina  
(antimoniales pentavalentes) 
Blockage of kinases of glycolysis (py-
ruvate kinase) 
 Trypanosoma spp. 
Leishmania spp. 
Suramin 
 
Inhibits glucose 6-phosphate dehydro-
genase (G6PD) of the route of the pen-
toses 
 Tryopanosoma spp. 
Nitazoxanide 
 
Inhibits pyruvate: ferredoxin óxido-
reductase (PFOR) 
 Cryptosporidium spp. 
Giardia lamblia 
Primaquine 
Atovaquone 
Blockage of mitocondrial transport of 
electrons, thus interfering with respirato-
ry chain  
 Plasmodium vuivax 
Plasmodium ovale 
Toxopolasma gondii 
Enzymes not related to 
energetic metabolism 
Chloroquine Inhibits hemopolymerase of the parasite 
and intoxicates it with iron, since it in-
creases concentration of 
ferriprotoporphyin IX 
Protozoans 
(sporozoos-
coccidia) 
Plasmodium spp. 
 
Eflornithine Interferes in the biosynthesis of polyam-
ines, irreversibly blocking la ornithine 
decarboxylase 
Trypanosoma spp. 
Of non-enzymatic pro-
teins related to micro-
tubular function 
Carbamates 
Benzimidazoles 
(albendazole, mebendazole, 
triclabendazole) 
Union to microtubules of the parasite, 
blocking assembly of tubulins. 
Alters secretion of acetylcholinesterase. 
Disminishes the incorporation of glucose 
to the parasite  
Helminths Trichuris trichiura 
Áscaris lumbricoides 
Of the neuromuscular 
function 
Levamisole 
Pyrantel  
Metrifonate 
Piperazine 
Diethylcarbamazine 
Ivermectin 
Praziquantel  
Interaction with the acetylcholine recep-
tor (ACh), blocking the neuromuscular 
system of the parasite, increasing perme-
ability in the membrane of the parasite, 
creating chlorine channels; ivermetic is 
also a GABA agonist  
Necator americanus 
Ancylostoma duodenale 
Enterobius vermicularis 
Wuchereria brancofti 
Strongyloides stercolaris 
Onchocerca volvulus 
Toxocara spp. 
Fasciolopsis buski 
Hymenolepis spp. 
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Table 3: Biochemical mechanisms for selective action of the main anti-protozoan drugs in humans (25) 
 
Antiparasitic drugs Parasite Biochemical mechanism 
Chloroquine 
Pentamidine 
Protozoans 
(sporozoos-coccidia) 
Different intake or secretion of the compound between the 
cell of the parasite and of the host 
Metronidazole 
 
Amoebas 
Ciliates: balantidiasis 
Protozoans anaerobic: blastocystosis, giardia-
sis, trichomoniasis 
Drug activates only within the parasite 
Nifurtimox sporozoos (coccidia) 
Chagas disease or trypanosomiasis 
Suramina Protozoans flagellates Site of action present only in parasite cell 
Albendazole 
Eflornithine 
Helminthhs, microsporidia 
Protozoans flagellated (american trypanosomi-
asis or Chagas disease) 
Different targets within the parasite and in the host 
Antimonials pentavalent 
Melarsoprol 
Tissue protozoans : leishmaniasis, African 
trypanosomiasis 
Greater toxic effect in the parasite than in the host 
 
Secondary effects of antiparasitic drugs lead 
to incompletion of treatment by the choice of 
the patient, which aggravates the risk of prop-
agation of resistant strains and the evasion of 
the host’s immune system due to the presence 
of variations on the surface proteins of the 
parasite. Therefore, the development of vac-
cines is an important challenge for the control 
of infections caused by parasites (24). 
Research strategies for antiparasitics mainly 
consider the study of genes that codify en-
zymes involved in activation mechanisms of 
antiparasitic drugs, inhibition of important 
cellular functions, induction of programmed 
parasite death, study of the factors of viru-
lence or pathogenicity, among others (26). 
 
Pharmacogenomics and antiparasitics  
Pharmacogenomics is a concept mentioned 
in literature since 1997. Before this year, the 
term “pharmacogenetics” (coined by Friedrich 
Vogel in 1959) was of common use, but be-
cause the acceptance of the definition of terms 
has not been formally established yet, authors 
use the words indistinctly27. 
A consensus to differentiate the connota-
tions of both terms is that “phar-
macogenomics” considers the polygenic effect 
over the safe and effective response towards 
drugs, as well as there adverse effects, where 
“pharmacogenetics” approaches a monogenic 
effect that influences in the variability of 
pharmacological metabolism (28).  
Currently, pharmacogenetics is viewed as a 
branch of pharmacology that delves into ge-
netic variability and its relation to the diverse 
interindividual and interpopulational respons-
es towards drugs (29). The field of application 
of pharmacogenomics in drugs includes an-
tiparasitics (Fig. 2). 
Genetic variability, which distinguishes every 
single person, shows a difference as low as 
0.1% in human genome; in other words, we 
share a genome with a similarity of 99.9% (30). 
Genetic variability is established based on 
simultaneous existence in a population of ge-
nomes having distinct alleles for a particular 
locus. These changes are called “polymor-
phisms” and their presence in the human ge-
nome is approximately of 10-30 million (31). 
The genetic difference, which distinguishes 
one human from other human beings, is ex-
pressed in various degrees, although not nec-
essarily in a cause-effect scenario. Within the 
genetic variability among individuals and pop-
ulations, there are phenotypical systems such 
as the ABO system, height, and eye color, to 
mention some. Other notable contrasts due to 
our genetic variability are the susceptibility to 
different diseases, as well as the diverse phar-
macokinetic responses to drugs (30). 
In this manner, the influence of variations in 
the genes that codify enzymes which corre-
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spondingly metabolize drugs leads to the ap-
pearance of adverse reactions after the admin-
istration of a drug, as well as in the rise of fre-
quency in collateral effects, exacerbation of 
physiological reactions, resistance to treatment, 
susceptibility to diseases, alterations in drug 
metabolism, changes in drug transporters, 
modifications in receptors, among others (32) 
(Fig. 3).  
 
 
 
Fig. 2: Field of application of pharmacogenomics 
in antiparasitics 
 
 
 
Fig. 3: Effect of the genetic variability in the me-
tabolism of antiparasitic drugs (41) 
 
A drug can be affected both in its pharma-
cokinetics and pharmacodynamics by the di-
verse genetic variations, and this is one of the 
factors that could explain why a given dose of 
a drug does not produce the desired effect in a 
group of patients, but instead it leads to toxici-
ty in another and, in some cases, presents in-
teractions with other drugs (32). 
Only 25% to 60% of patients have an effec-
tive and safe response to the majority of drugs 
(33), including antiparasitics; the remaining 
percentage presents adverse drugs reactions 
(34). The WHO defines said reactions as 
“whatever response to a drug that is harmful, 
non-intended and that is produced at habitual 
doses for prophylaxis, diagnosis or treatment” 
(35). 
The global notification program for adverse 
drug reactions was created in the 1960s by the 
WHO and accounts for 119 countries nowa-
days. Mexico began its participation in the 
program in 1999. The information is collected 
by pharmacies, the pharmaceutical industry, 
hospital pharmacovigilance units and state 
centers. It is provided through the National 
Center of Pharmacovigilance (CNFV) that 
depends directly from the Federal Commis-
sion for the Protection against Sanitary Risks 
(COFEPRIS) of the Secretary of Health, 
which reunites and directs the information to 
the surveillance center in Uppsala, Sweden, 
which is the operational coordinator of the 
drug surveillance program for the WHO (36-
39). 
Besides the genetics of the individuals, the 
interindividual variability in the response to 
drugs is multifactorial, comprising factors 
such as age, sex, ethnicity, anthropometry, 
lifestyle, diet, stress, drug interactions, previ-
ous or concomitant diseases. 
Furthermore, drugs can provoke genome 
variations, such as the intermediary reduced 
hydroxylamine, which is a potential mutagen 
that is formed in the endogenic process in-
volved in the reduction of metronidazole mol-
ecule, and for which the capability of generat-
ing punctual mutations has been proposed 
(40). 
In the present day, the variations in around 
20 genes provide useful predictions of reac-
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tions to drugs for at least 7% of drugs (80 to 
100) approved by the FDA (34). 
Around 500 genes in our genome are related 
to the response and safety of drugs. These 
genes can be studied from a pharmacological 
point of view in a differential manner, such as 
pharmacokinetic genes, which are those des-
tined to codifying the proteins involved in the 
Absorption, Distribution, Metabolism and 
Elimination (ADME) process, among which 
enzymes of drug oxidative metabolism are 
found (isoforms of CYP), as well as plasmatic 
proteins and transporters, pharmacodynamic 
genes that implicate proteins, receptors, ion 
channels and immunomodulatory molecules 
(42, 43). 
A deep study of the genes involved in the 
pharmacokinetics and pharmacodynamics of 
the antiparasitics will allow for the discovery 
of therapeutic targets that assist in the search 
for personalized treatment, these approach 
does not imply a prescription based treatment, 
but rather the selection or exclusion of pa-
tients that could present adverse drug reac-
tions, for example patients showing poor, 
moderate or ultrarapid metabolisms. Phar-
macogenomics allow to evaluating genetic al-
terations that give way to a diversity of re-
sponses to provide a more safe and effective 
drug, at the correct dose for the appropriate 
patient and with an optimal treatment dura-
tion, besides assisting in the development of 
vaccines (44). 
 
Study of the genetic variability in the 
pharmacological response  
Whole Genome Association Studies (GWA) 
have demonstrated there is an association be-
tween single nucleotide polymorphisms (SNP) 
and parasitic disease. To identify and charac-
terize the causal genes, linking and association 
studies have been employed (46). 
Linking studies allow for the genotypifica-
tion of microsatellites distributed throughout 
the whole genome, leading to the identifica-
tion of genes presumably implicated in the 
physiology of the disease.  
The most commonly used polymorphism to 
identify these genes is SNP. The “case-
control” association studies are employed for 
the study of candidate genes, despite the fol-
lowing limitations (45, 46): 
 It lacks replicability in different 
populations 
 Small sample size  
 Low statistical power 
 Errors of genotypification 
 Lack of precision in the clinical 
characterization of the disease  
 Inadequate selection of the 
cases and controls 
 Presence of populational sub-
structure 
 
Markers of genetic variation towards an-
tiparasitics  
The biological variations related to the 
pharmacological response can appear in the 
genes that codify for the therapeutic targets, 
for the transporters and/or metabolizing en-
zymes. The genes, which codify enzymes re-
lated to the pharmacokinetics of the antipara-
sitics, are mainly related to the metabolism, 
transporters, plasmatic proteins and transcrip-
tion factors. 
The most common type of variations is SNP. 
Also variations in the gene of the human 
leucocitary antigen (HLA) and in the number 
of copies (CNVs) (47). 
The variation in pharmacological response 
can be explained by the polymorphic variants 
in the codifying genes for: 
a. Metabolizing enzymes for cy-
tochrome p450  
b. Transporters that allow the en-
try or facilitate the exit of drugs 
through the cell membrane 
c. Receptors 
d. Ion channels 
e. Plasmatic union proteins (al-
bumin, acidic α-glycoprotein) 
f. Regulators and factors of tran-
scription 
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Metabolism of antiparasitic drugs is mainly 
modified by variation in cytochrome p450 en-
zymes. These enzymes present a high frequen-
cy in polymorphic variability, which affects the 
expression of the isoforms CYP2C, CYP1A, 
CYP34A, CYP2D6, CYP2E1 and CYP2A6 
(Table 4). The form of expression of the poly-
morphisms in the isoforms mentioned is relat-
ed to those patients that metabolize poorly 
(5%-10%), intermediate metabolizers (10%-
15%) or ultrarapid metabolizers (2%-7%). 
Polymorphisms in the transporters can in-
fluence the codifying genes for transporters of 
ATP union (also called “ABC” transporters), 
genes for carrier transporters of solutes (SLC) 
or genes codifying for glycoprotein P (PgP), 
related to the efflux of xenobiotics and proba-
ble drug resistance. 
In consequence, understanding the way in 
which antiparasitics interact with the pharma-
cological target facilitates the development of 
new and more efficient drugs. Thus we must 
consider the mechanism of action of the 
chemotherapeutic agent that relates to: 
 Transporters (of influx and efflux) 
 Metabolism (pharmacological poten-
cy) 
 Pharmacological targets (enzymes, 
protein complexes, and metabolites) 
With respect to transport of drugs, generally 
antiparasitics enter cells by passive transport 
mechanism, through membrane channels and 
transporters; a modification of these can mod-
ify drug specificity (48-55). 
 
Table 4: Interactions of induction or inhibition over cytochrome p450 (CYP) intestinal antiparasitic drugs 
commonly used in Mexico with substrates of the CYP administered with these drugs (55-58). 
 
Antiparasitic drugs CYP Gene 
 1A1 1A2 2C8 2C9 2C19 2D6 3A4 3A5 3A4*3 3A7 19A 
Metronidazole   Inh Inh 
S 
  Inh 
S 
    
Clotrimazole   Inh Inh   Inh 
Ind 
    
Tinidazole       S    Inh 
Albendazole Inh Inh 
S 
Ind 
    S     
Tiabendazole Ind Inh 
S 
         
Mebendazole Ind      S     
Fenbendazole  Ind          
Pyrantel-oxantel      S      
Emetine      S 
Ind 
S 
Ind 
    
Praziquantel  S   S Inh S S S S  
 
Conclusion 
 
Genetic variability contributes to 
interindividual diversity in the response to 
drugs. Enzymes that metabolize the majority 
of the antiparasitic drugs happened to be codi-
fied by genes that present genetic polymor-
phism. These polymorphic enzymes can cause 
alterations to the pharmacokinetics of the 
drug. In particular, they can alter the metabo-
lism of antiparasitic drugs such as metronida-
zole, albendazole, mebendazole, emetine, pra-
ziquantel, which are among the most-used an-
tiparasitic drugs in Mexico. The better under-
standing of the pharmacogenetics of antipara-
sitic drugs contributes to more accurate deci-
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sion making in the selection of an antiparasitic 
drug, which lowers the risk of presentig ad-
verse reactions. This is the search for person-
alized therapy. 
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